Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Montreal, QC, CA. The stock last traded at $1.27, up 0.79% on the session, giving a market capitalisation of $158.1M. On trailing twelve-month figures it carries a trailing P/E of -1.87, a net margin of -3832.0%. Its beta of 0.97 implies it has historically moved less than the broad market.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.
Milestone Pharmaceuticals Inc. is most often compared with the following Healthcare names: